Sagimet Biosciences Inc. (SGMT)
Sagimet Biosciences Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in San Mateo, CA, US. The stock last traded at $9.08, down 5.61% on the session, giving a market capitalisation of $648.0M. On trailing twelve-month figures it carries a trailing P/E of -7.63, a net margin of 0.0%. Its beta of 3.47 implies it has historically moved more than the broad market.
Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops novel therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic and fibrotic pathways in the United States. The company’s lead drug candidate is Denifanstat, an oral, once-daily pill and selective FASN inhibitor for the treatment of metabolic dysfunction-associated steatohepatitis, acne, and select forms of cancer. It also develops TVB-3567, a FASN inhibitor for the treatment of acne indication; and other oncology programs, such as solid tumor and glioblastoma. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019. Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California.
Sagimet Biosciences Inc. is most often compared with the following Healthcare names: